GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Isleworth Healthcare Acquisition Corp (NAS:ISLE) » Definitions » Interest Income

Isleworth Healthcare Acquisition (Isleworth Healthcare Acquisition) Interest Income : $0.41 Mil (TTM As of Jun. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Isleworth Healthcare Acquisition Interest Income?

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. Isleworth Healthcare Acquisition's interest income for the three months ended in Jun. 2022 was $0.30 Mil. Its interest income for the trailing twelve months (TTM) ended in Jun. 2022 was $0.41 Mil.

Isleworth Healthcare Acquisition Interest Income Historical Data

The historical data trend for Isleworth Healthcare Acquisition's Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Isleworth Healthcare Acquisition Interest Income Chart

Isleworth Healthcare Acquisition Annual Data
Trend Dec20 Dec21
Interest Income
- 0.06

Isleworth Healthcare Acquisition Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Interest Income Get a 7-Day Free Trial 0.02 0.01 0.03 0.07 0.30

Isleworth Healthcare Acquisition Interest Income Calculation

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.

Interest Income for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.41 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Isleworth Healthcare Acquisition (Isleworth Healthcare Acquisition) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Isleworth Healthcare Acquisition Corp (NAS:ISLE) » Definitions » Interest Income
Comparable Companies
AVAC TRCA IFIN WAVC IQMD FRW SHCA OCA BIOT DWIN GSHN PSTH XAMS:EPIC ASZ CCYC CVII KAHC DWAC IPOF PBAJ
Traded in Other Exchanges
N/A
Address
360 Central Avenue, First Central Tower, Suite No. 800, Saint Petersburg, FL, USA, 33701
Website
https://www.isleworthhealthcare.com
Isleworth Healthcare Acquisition Corp is a blank check company.

Isleworth Healthcare Acquisition (Isleworth Healthcare Acquisition) Headlines

From GuruFocus

Cytovia Therapeutics presents antitumor activity of its CD38-Targeting Flex-NK� Cell Engager antibody at EHA 2022 Congress

By PRNewswire PRNewswire • 06-20-2022

ISLEWORTH AND CYTOVIA TERMINATE MERGER AGREEMENT

By PRNewswire PRNewswire • 06-30-2022

Cytovia Therapeutics to Present In Vivo Multiple Myeloma Data of its CD38-Targeting Flex-NK� Cell Engager at EHA 2022 Congress

By PRNewswire PRNewswire • 06-07-2022

Isleworth Healthcare Acquisition Corp. Announces Closing of $207,000,000 Initial Public Offering, Including Full Exercise of Underwriter Over-Allotment Option

By PRNewswire PRNewswire • 03-03-2021

Isleworth Healthcare Acquisition Corp. Announces Cancellation of Special Meeting of Shareholders, Redemption of Public Shares and Subsequent Dissolution

By PRNewswire PRNewswire • 08-25-2022

Cytovia Therapeutics to Present at AACR Special Conference on Advances in the Pathogenesis and Molecular Therapies of Liver Cancer

By PRNewswire PRNewswire • 05-16-2022

Cytovia Therapeutics to Present In Vivo Multiple Myeloma Data of its CD38-Targeting Flex-NK� Cell Engager at EHA 2022 Congress

By PRNewswire PRNewswire • 06-27-2022

Cytovia Therapeutics to Present In Vivo Multiple Myeloma Data of its CD38-Targeting Flex-NK� Cell Engager at EHA 2022 Congress

By PRNewswire PRNewswire • 06-17-2022

ISLEWORTH AND CYTOVIA TERMINATE MERGER AGREEMENT

By PRNewswire PRNewswire • 07-10-2022

Cytovia Therapeutics to Present at AACR Special Conference on Advances in the Pathogenesis and Molecular Therapies of Liver Cancer

By PRNewswire PRNewswire • 05-06-2022